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Calciﬁc aortic valve stenosis (CAVS) is the most common
form of acquired valvular heart disease, present in 3% of the
population more than 75 years of age (1). Although risk
factors are similar for CAVS and atherosclerosis, w50% of
patients with CAVS do not have clinically signiﬁcant
cardiovascular disease (CVD), suggesting related, but unique,
pathophysiology (1). Although surgical aortic valve re-
placement remains the gold standard treatment for most
patients, at least one-third of symptomatic patients with
CAVS may not undergo surgical aortic valve replacement.
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To ﬁll this clinical need, transcatheter aortic valve
replacement is increasingly being used, but overall survival
remains modest due to the advanced age and other comor-
bidities. With the aging of the population, the prevalence of
CAVS will increase rapidly and portends medical, ﬁnancial,
and ethical burdens to healthcare systems worldwide. Hence,
identiﬁcation of causal pathways mediating CAVS may
provide novel targets for earlier therapy before end-stage
disease. One of these pathways may involve the lipo-
protein(a) (Lp[a]), lipoprotein-associated phospholipase A2
(Lp-PLA2), and oxidized phospholipids (OxPL) axis (2).*Editorials published in the Journal of the American College of Cardiology reﬂect the
views of the authors and do not necessarily represent the views of JACC or the
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disclose.Lp(a) is composed of apolipoprotein B-100 (apoB)
covalently bound to apolipoprotein(a) [apo(a)]. On the
basis of recent meta-analyses, genome-wide association
study (GWAS), and Mendelian randomization studies,
Lp(a) is now generally considered a causal risk factor for
CVD (3). Recently, Thanassoulis et al. (4) showed in
a GWAS study of multiple ethnic groups that genetic
variation at the LPA gene locus, as manifested by single
nucleotide polymorphism (SNP) rs10455872, was caus-
ally related to CAVS. Lp(a) is proatherogenic because of
its low-density lipoprotein (LDL) moiety and through
additional mechanisms mediated by apo(a) (3,5,6). A key
proinﬂammatory property of Lp(a) may be its content of
OxPL (7,8). Among lipoproteins, OxPL is predominantly
found on Lp(a), with only small amounts on LDL and
high-density lipoprotein (HDL) (8,9). A large clinical
database supports the hypothesis that the risk of Lp(a) is
driven by its content of OxPL, mainly present on small
apo(a) isoforms associated with high Lp(a) levels (7).
Elevated levels of OxPL on apoB (OxPL/apoB) predict
death, myocardial infarction, and stroke, reclassify w30%
of patients to different risk categories, and reﬂect extent of
CVD in multiple arterial beds (10).
Lp-PLA2 hydrolyzes OxPL to yield a free oxidized
fatty acid (OxFA) and lysophosphatidylcholine (11). Both
the precursor (OxPL) and the 2 byproducts of Lp-PLA2
manifest proinﬂammatory effects. It has not been established
which is more clinically relevant, and clinical trials are being
performed to assess whether inhibiting breakdown of OxPL
with the Lp-PLA2 inhibitor darapladib will improve clinical
outcomes. Lp-PLA2 is secreted by inﬂammatory cells and
circulates primarily on LDL, but is also present on HDL
and Lp(a), increasing proportionally on Lp(a) with higher
Lp(a) levels (9). On average, it has been estimated that only
1 of 100 LDL particles carries Lp-PLA2 (11). However, on
an equimolar basis, Lp(a) has a 1.5-fold to 2-fold higher
mass of Lp-PLA2 and as much as a 7-fold higher speciﬁc-
activity than LDL (12,13). Lp-PLA2 mass and activity
independently predict CVD events, and this risk is
approximately doubled when Lp(a) and/or OxPL/apoB are
also elevated (14), suggesting a common pathophysiological
link. Interestingly, Lp-PLA2 on HDL is associated with
lower CVD risk (15), whereas on LDL, it is associated with
higher risk. Overall, these observations suggest plausible
mechanisms through which Lp(a)–Lp-PLA2–OxPL may
mediate CAVS, as has been suggested for atherosclerosis
and cardiovascular disease (2). In this issue of the Journal, 2
reports provide such evidence (16,17).
In the ﬁrst paper, Kamstrup et al. (16) conﬁrm and
extend the ﬁndings of Thanassoulis et al. (4) by showing
that elevated Lp(a) levels (>74 mg/dl, representing w10%
to 15% of the general population) were independently
associated with CAVS, predicting a 3-fold increased risk.
Consistent with genetic causality, carriers of LPA SNPs
rs10455872 and rs3798220 and of low number of KIV-2
repeats, all of which are associated with higher Lp(a)
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479levels, were also associated with CAVS. The enhanced risk
was driven by high Lp(a) levels and not an independent risk
of the LPA SNPs. Lp(a) levels ﬂuctuate minimally
throughout life within pre-set genetically determined levels
and are mediated almost exclusively by the LPA gene,
including various LPA SNPs and variability in KIV-2
repeats. The relatively unchanging levels of Lp(a) among
populations are akin to randomization in a trial with a
therapy that results in signiﬁcant on-treatment differences
in Lp(a) levels.
In the second paper, Mahmut et al. (17) provide physical
evidence that Lp-PLA2 may play a role in CAVS. They
evaluated 40 surgically excised stenotic aortic valves and 20
noncalciﬁed aortic valves obtained after heart trans-
plantation, and documented higher expression of Lp-PLA2
at the transcription, protein, and activity level. Presumably,
Lp-PLA2 in the valves was derived from local secretion by
inﬂammatory cells and also transported by LDL and Lp(a).
Lp(a) has strong lysine binding sites and, after entering
through disruptions in the endothelial layer of the valve
leaﬂets, may accumulate and promote inﬂammation through
several pathways (1,3). Mahmut et al. (17) further docu-
mented histological colocalization with OxLDL and lyso-
phosphatidylcholine, and noted modest correlations of
Lp-PLA2 with indices of valve remodeling and hemody-
namic severity of CAVS. Although this study is done well
overall, several caveats should be borne in mind. One, it
cannot be determined whether these observations are cause
or consequence of CAVS, and trials to inhibit Lp-PLA2
and assess effect on CAVS will be needed. Based on the fact
that the gene that encodes Lp-PLA2, PLA2G7, was not
apparently associated with CAVS in the recent GWAS
study by Thanassoulis et al. (4) suggests it may not be
a causal mechanism. Nonetheless, it may still play a role in
CAVS progression to clinical symptoms. Two, the cor-
relations of CAVS Lp-PLA2 expression with plasma
Lp-PLA2 and OxLDL were not adjusted for LDL
cholesterol, Lp(a), HDL cholesterol, or apoB levels and
may simply reﬂect higher levels of such particles, with their
cargo of Lp-PLA2, entering valve tissue from the circula-
tion. Three, the antibody used in the OxLDL assay binds
a conformational epitope of apoB rather than OxPL.
Therefore, it does not necessarily reﬂect OxPL plasma
levels, which would be important to link it to Lp-PLA2
pathophysiologically. It is also underappreciated that this
antibody cross reacts with apoB at levels widely present in
humans (18) and may not measure, only OxLDL, but also
apoB in plasma, as has been shown by experiments showing
that samples of known content of OxLDL when spiked
with unoxidized LDL result in a proportional increase in
OxLDL levels (19). And four, most patients had bicuspid
aortic stenosis, and it would be important to conﬁrm such
ﬁndings in a larger number of patients with tricuspid
CAVS. However, it is possible that Lp(a)-Lp-PLA2-
OxPL may be particularly important pathophysiologically
in bicuspid aortic valve stenosis.Valvular calciﬁcation precedes the development of
CAVS and is actively regulated. Oxidative stress, calciﬁc
nodules, and inﬂammatory inﬁltrates play a signiﬁcant role
in CAVS (1), and the accumulation of OxLDL is associ-
ated with increased inﬂammation and may potentiate
calciﬁcation and matrix remodeling (20,21). Treatment of
calcifying aortic smooth muscle cells with OxPL has been
shown to stimulate expression of alkaline phosphatase
and formation of cellular aggregates containing calcium
mineral, characteristic features of osteoblastic differentia-
tion (22,23). Recently, OxLDL and Lp(a) have been
shown to bind monocyte chemoattractant protein-1, which
may play a role in attracting monocytes to subendothelial
spaces (24).
There is currently no medical therapy to prevent or
reduce the progression of CAVS in humans. Studies in
hypercholesterolemic Ldlr–/– mice have shown that CAVS
develops and that lowering cholesterol earlier in the course
of disease progression will retard aortic stenosis, but if
begun much later, will not inﬂuence the extent of stenosis
(25,26). Retrospective human studies have suggested statins
are effective in reducing progression. However, prospective
randomized human trials, including the SALTIRE (Scot-
tish Aortic Stenosis Lipid lowering Therapy Impact on
Regression study, atorvastatin 80 mg/dl), SEAS (Simvas-
tatin and Ezetimibe in Aortic Stenosis study, (simvastatin
40mg/dl plus ezetimibe 10mg/dl) and theASTRONOMER
(Aortic Stenosis Progression Observation: Measuring Effects
of Rosuvastatin study, rosuvastatin 40 mg/dl), have shown
no signiﬁcant effect on CAVS progression. (1). There are
several possibilities for the negative results, including that
treatment of elderly patients studied in these trials, who
already had moderate to heavily calciﬁed valves at the end
stage of the disease, was too late to inﬂuence disease
outcomes. Therefore, therapeutic agents beyond standard
lipid-lowering therapy are needed to have an impact on
CAVS.
The preceding observations suggest that targeting the
Lp(a)–Lp-PLA2–OxPL pathways may be a viable app-
roach in mitigating CAVS. That could be done by several
currently available approaches targeting Lp(a), including
antisense oligonucleotides speciﬁcally directed to apo(a) of
Lp(a) currently in phase 1 trials, which lower Lp(a) levels
>85% (27), inhibitors of Lp-PLA2 such as darapladib
currently being evaluated in phase 3 trials in patients with
acute coronary syndromes and stable coronary artery
disease, and therapies to prevent oxidation of lipoproteins
or minimize their proinﬂammatory effects, such as sufﬁ-
cient antioxidants, oxidation-speciﬁc antibodies targeting
OxPL, and other immunomodulatory agents (28,29). It
also sets the stage for the discovery of new therapeutic
agents.
In summary, these studies signiﬁcantly enhance our
understanding of the development of CAVS by highlighting
the potential role of the Lp(a)-Lp-PLA2–OxPL axis as
mediators of CAVS and suggesting new therapeutic targets.
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480These targets can initially be validated in animal models and
ultimately in randomized clinical trials.
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